Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2015

View Archived Issues

GlaxoSmithKline presents highlights of third quarter 2015

Taiho starts phase I trial of TAS-303 in women with stress urinary incontinence

Vertex profiles pipeline progression in third quarter 2015

Isis Pharmaceuticals begins phase II study of ISIS-FXIRx in end-stage renal disease

Alexza to regain U.S. rights to Adasuve from Teva

Quark Pharmaceuticals plans new trials of QPI-1002

Q BioMed signs definitive license agreement for Mannin's platform technology assets

T-2762 shows efficacy for the treatment of dry eye syndrome

Sylentis identifies siRNA for treating allergic conjunctivitis

Significant activity seen with ustekinumab in Crohn's disease without TNF-antagonist resistance

XuanZhu Pharma patents EGFR inhibitors

Merck & Co. and Mochida develop FIXa inhibitors

University of California at Chapel Hill reports MerTK/TYRO3 inhibitors

Aileron Therapeutics discloses PTH1R antagonists

Kainos Medicine divulges Brd4 inhibitors

The Lung Cancer Research Foundation announces the award of 28 grants

Novel gene mutations associated with disease and developmental disorders reported at ASHG

Kite Pharma begins phase II ZUMA-1 trial

Glenmark and Genzyme report clinical results for vatelizumab in multiple sclerosis

Merck & Co. receives FDA breakthrough therapy designation for Keytruda in colorectal cancer

European approval for Eylea for the treatment of visual impairment due to myopic CNV

Novel biomarkers for gastrointestinal disorders discovered

SL-401 receives E.U. orphan drug designation for blastic plasmacytoid dendritic cell neoplasm

University of Oxford starts first-in-human study of prime-boost malaria vaccine

AGTC files IND application for the treatment of achromatopsia

Shire to acquire Dyax

BMS agrees to acquire Cardioxyl Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...